Assessment of the Disease Severity and Treatment Patterns of Rheumatoid Arthritis in Eastern Europe, Middle East and North African Countries (P08167)

Cross-sectional Study of Disease Severity and Treatment Patterns of Rheumatoid Arthritis, in Eastern Europe Middle East and North Africa

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01313871

Enrollment

Registered

2011-03-14

Start date

2011-08-31

Completion date

2012-11-30

Last updated

2015-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthritis, Rheumatoid

Brief summary

The study will assess the disease severity and treatment patterns of rheumatoid arthritis in Eastern European, Middle Eastern, and North African countries.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

: * Confirmed diagnosis of rheumatoid arthritis, preferably based upon criteria established by the American College of Rheumatology (ACR) 1987 * clinical signs & symptoms * data obtained from previous laboratory and instrumental examination, which may include but is not limited to: Radiography, Blood tests * Written informed consent, signed before participation in the study.

Exclusion criteria

: * Refusal to participate in the study * Age under 18 years

Design outcomes

Primary

Measure	Time frame
Number of participants with low, moderate, or high disease activity as assessed by the Disease Activity Score using 28 joint counts (DAS28)	Day of enrollment (Day 0)

Secondary

Measure	Time frame
The number of participants with rheumatoid arthritis visiting participating sites in the course of one year	One year
Number of participants with different degrees of disability as assessed by the Health Assessment Questionnaire (HAQ).	Day of enrollment (Day 0)
Number of participants treated with non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDS), corticosteroids, and/or biologics	Day of enrollment (Day 0)

Outcome results